• Baricitinib, an anti-JAK1/JAK2, reduces cytokine release and SARS-Co-V2 entry; • In a retrospective multicenter study baricitinib reduces COVID-19 mortality rate; • Baricitinib reduces Intensive Care Unit admissions of COVID-19 pneumonia; • Baricitinb reduces SARS-CoV-2 viral burden detected by nasopharyngeal swab; • Baricitinib used for 2 weeks was not associated with serious adverse events.